23870086 22760537 26073782 29395887 21273012 27164941 24231153 33657636 21919115 34478568 29130355 26780032 21817948 22184649 24921044 25070304 22504840 26889568 25308481 24126903 21193846 25706618 30379957 21300647 - Search Results

Year	Number of Results
2010	1
2011	4
2012	5
2013	4
2014	2
2015	4
2016	2
2017	1
2018	3
2021	2
2022	1

1

Association of RSV-related hospitalization and non-compliance with palivizumab among commercially insured infants: a retrospective claims analysis.

Stewart DL, Ryan KJ, Seare JG, Pinsky B, Becker L, Frogel M. Stewart DL, et al. BMC Infect Dis. 2013 Jul 19;13:334. doi: 10.1186/1471-2334-13-334. BMC Infect Dis. 2013. PMID: 23870086 Free PMC article.

2

Adherence to guidelines for respiratory syncytial virus immunoprophylaxis among infants with prematurity or chronic lung disease in three United States counties.

Carroll KN, Griffin MR, Edwards KM, Ali A, Zhu Y, Iwane MK, Szilagyi PG, Staat MA, Stevens TP, Hall CB, Williams JV, Hartert TV. Carroll KN, et al. Pediatr Infect Dis J. 2012 Nov;31(11):e229-31. doi: 10.1097/INF.0b013e318266bf89. Pediatr Infect Dis J. 2012. PMID: 22760537 Free PMC article.

3

Infants born before 32 weeks of gestation or with respiratory disease are most likely to receive palivizumab in the Netherlands.

Kool-Houweling LM, Penning-van Beest FJ, Bezemer ID, van Lingen RA, Herings RM. Kool-Houweling LM, et al. Acta Paediatr. 2015 Sep;104(9):927-32. doi: 10.1111/apa.13081. Epub 2015 Jul 23. Acta Paediatr. 2015. PMID: 26073782

4

Palivizumab administration in preterm infants in France: EPIPAGE-2 cohort study.

Torchin H, Rousseau J, Marchand-Martin L, Truffert P, Jarreau PH, Ancel PY. Torchin H, et al. Arch Pediatr. 2018 Feb;25(2):89-94. doi: 10.1016/j.arcped.2017.12.009. Epub 2018 Feb 1. Arch Pediatr. 2018. PMID: 29395887

5

Special populations: do we need evidence from randomized controlled trials to support the need for respiratory syncytial virus prophylaxis?

Paes B, Manzoni P. Paes B, et al. Early Hum Dev. 2011 Mar;87 Suppl 1:S55-8. doi: 10.1016/j.earlhumdev.2011.01.012. Epub 2011 Jan 26. Early Hum Dev. 2011. PMID: 21273012 Review.

6

Administration of Palivizumab in the NICU.

Vendetti N, Gerber JS, Sammons JS, Fisher BT, Zaoutis TE, Coffin SE. Vendetti N, et al. Hosp Pediatr. 2016 Jun;6(6):354-8. doi: 10.1542/hpeds.2015-0238. Epub 2016 May 10. Hosp Pediatr. 2016. PMID: 27164941

7

Is palivizumab effective as a prophylaxis of respiratory syncytial virus infections in cystic fibrosis patients? A meta-analysis.

Sánchez-Solis M, Gartner S, Bosch-Gimenez V, Garcia-Marcos L. Sánchez-Solis M, et al. Allergol Immunopathol (Madr). 2015 May-Jun;43(3):298-303. doi: 10.1016/j.aller.2013.09.003. Epub 2013 Nov 11. Allergol Immunopathol (Madr). 2015. PMID: 24231153 Review.

8

Respiratory Syncytial Virus Immunoprophylaxis with Palivizumab: 12-Year Observational Study of Usage and Outcomes in Canada.

Mitchell I, Li A, Bjornson CL, Lanctot KL, Paes BA; CARESS investigators. Mitchell I, et al. Am J Perinatol. 2021 Mar 3. doi: 10.1055/s-0041-1725146. Online ahead of print. Am J Perinatol. 2021. PMID: 33657636 Free article.

9

Effectiveness of palivizumab prophylaxis in infants and children in Florida.

Winterstein AG, Hampp C, Saidi A. Winterstein AG, et al. Pharmacoepidemiol Drug Saf. 2012 Jan;21(1):53-60. doi: 10.1002/pds.2246. Epub 2011 Sep 15. Pharmacoepidemiol Drug Saf. 2012. PMID: 21919115

10

Access to palivizumab among children at high risk of respiratory syncytial virus complications in English hospitals.

Zylbersztejn A, Almossawi O, Gudka N, Tompsett D, De Stavola B, Standing JF, Smyth R, Hardelid P. Zylbersztejn A, et al. Br J Clin Pharmacol. 2022 Mar;88(3):1246-1257. doi: 10.1111/bcp.15069. Epub 2021 Oct 7. Br J Clin Pharmacol. 2022. PMID: 34478568

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results